{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:53:25Z","timestamp":1788785605208,"version":"build-2803163510"},"reference-count":17,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The use of thyroglobulin (Tg) and thyroglobulin antibodies (TgAb) for detecting disease recurrence is well validated following total thyroidectomy and radioiodine ablation. However, limited data are available for patients treated with thyroid lobectomy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients who had lobectomy for papillary thyroid cancer followed for &amp;gt;1 year, with sufficient data on Tg and TgAb, including subgroup analysis for Hashimoto\u2019s thyroiditis and contralateral nodules.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One-hundred sixty-seven patients met the inclusion criteria. Average tumor size was 9.5\u2005\u00b1\u20056 mm. Following lobectomy, Tg was 12.1\u2005\u00b1\u200514.8 ng\/mL. Of 52 patients with Hashimoto\u2019s thyroiditis, 38% had positive TgAb with titers of 438\u2005\u00b1\u2005528 IU\/mL, and in patients without TgAb the mean Tg level was 14.7\u2005\u00b1\u200519.0 ng\/mL. In 34 patients with contralateral nodules \u22651 cm, Tg was 15.3\u2005\u00b1\u200517 ng\/mL. During the first 2 years of follow-up, Tg declined \u22651 ng\/mL in 42% of patients (by 5.1\u2005\u00b1\u20053.7 ng\/mL), remained stable in 22%, and increased in 36% (by 4.9\u2005\u00b1\u20055.7 ng\/mL). During a mean follow-up of 6.5 years (78\u2005\u00b1\u200543.5 months), 18 patients had completion thyroidectomy and 12 were diagnosed with contralateral cancer (n\u2005=\u20058) or lymph node metastases (n\u2005=\u20054). In patients with recurrence followed for &amp;gt;2 years, there was a rise in Tg in 3 cases, Tg was stable in 2 cases, and in 1 TgAb decreased from 1534 to 276 IU\/mL despite metastatic lymph nodes. Basal Tg and Tg dynamics did not predict disease recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Serum thyroglobulin used independently is of limited value for predicting or detecting disease recurrence following thyroid lobectomy. Other potential roles of Tg, such as detecting distant metastases following lobectomy, should be further studied.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa152","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T06:19:21Z","timestamp":1585289961000},"page":"e2145-e2151","source":"Crossref","is-referenced-by-count":61,"title":["Detecting Recurrence Following Lobectomy for Thyroid Cancer: Role of Thyroglobulin and Thyroglobulin Antibodies"],"prefix":"10.1210","volume":"105","author":[{"given":"Amit","family":"Ritter","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviram","family":"Mizrachi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Bachar","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Vainer","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[{"name":"Endocrinology & Metabolism Institute, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Endocrinology & Metabolism Institute, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Diker-Cohen","sequence":"additional","affiliation":[{"name":"Endocrinology & Metabolism Institute, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Duskin-Bitan","sequence":"additional","affiliation":[{"name":"Endocrinology & Metabolism Institute, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-4212","authenticated-orcid":false,"given":"Eyal","family":"Robenshtok","sequence":"additional","affiliation":[{"name":"Endocrinology & Metabolism Institute, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"issue":"12","key":"2021122105120255000_CIT0001","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2010.0178","article-title":"Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid."},{"issue":"3","key":"2021122105120255000_CIT0002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1530\/EJE-11-0466","article-title":"Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients","volume":"165","author":"Castagna","year":"2011","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2021122105120255000_CIT0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/EJE-13-0524","article-title":"Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma","volume":"170","author":"Jeon","year":"2014","journal-title":"Eur J Endocrinol."},{"key":"2021122105120255000_CIT0004","doi-asserted-by":"crossref","first-page":"591285","DOI":"10.1155\/2014\/591285","article-title":"Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems","volume":"2014","author":"Cano-Palomares","year":"2014","journal-title":"Int J Endocrinol."},{"issue":"11","key":"2021122105120255000_CIT0005","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/MNM.0000000000000183","article-title":"Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation","volume":"35","author":"Hong","year":"2014","journal-title":"Nucl Med Commun."},{"issue":"11","key":"2021122105120255000_CIT0006","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/thy.2015.0121","article-title":"Implementing the modified 2009 American Thyroid Association risk stratification system in thyroid cancer patients with low and intermediate risk of recurrence","volume":"25","author":"Pitoia","year":"2015","journal-title":"Thyroid."},{"issue":"12","key":"2021122105120255000_CIT0007","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/MNM.0000000000000766","article-title":"Dynamic risk stratification for predicting the recurrence in differentiated thyroid cancer","volume":"38","author":"Ozkan","year":"2017","journal-title":"Nucl Med Commun."},{"issue":"1","key":"2021122105120255000_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid."},{"key":"2021122105120255000_CIT0009","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2019-00177","article-title":"Risk stratification in differentiated thyroid cancer: from detection to final follow-up","author":"Tuttle","year":"2019;104(9):4087-4100","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2021122105120255000_CIT0010","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1210\/jc.2015-4290","article-title":"Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine","volume":"101","author":"Momesso","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122105120255000_CIT0011","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1089\/thy.2016.0477","article-title":"Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy","volume":"27","author":"Park","year":"2017","journal-title":"Thyroid."},{"issue":"1","key":"2021122105120255000_CIT0012","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/cen.13721","article-title":"Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients","volume":"89","author":"Cho","year":"2018","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"8","key":"2021122105120255000_CIT0013","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1089\/thy.2018.0046","article-title":"Changes in serum thyroglobulin levels after lobectomy in patients with low-risk papillary thyroid cancer","volume":"28","author":"Park","year":"2018","journal-title":"Thyroid."},{"issue":"1","key":"2021122105120255000_CIT0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.surg.2018.04.078","article-title":"Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer","volume":"165","author":"Shaha","year":"2019","journal-title":"Surgery."},{"issue":"6","key":"2021122105120255000_CIT0015","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1210\/jc.2016-3983","article-title":"Letter to the editor: what is the role of serum thyroglobulin measurement in patients with differentiated thyroid cancer treated without radioactive iodine?","volume":"102","author":"Giovanella","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122105120255000_CIT0016","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/bjs.1800770329","article-title":"Measurement of serum thyroglobulin is of value in detecting tumour recurrence following treatment of differentiated thyroid carcinoma by lobectomy","volume":"77","author":"Harvey","year":"1990","journal-title":"Br J Surg."},{"issue":"8","key":"2021122105120255000_CIT0017","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4158\/EP-2018-0052","article-title":"Be aware of the patient with benign follicular thyroid lesion histology and rising thyroglobulin level","volume":"24","author":"Slutzky-Shraga","year":"2018","journal-title":"Endocr Pract."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa152\/32971851\/dgaa152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/6\/e2145\/41829566\/jcem_105_6_e2145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/6\/e2145\/41829566\/jcem_105_6_e2145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T05:12:19Z","timestamp":1640063539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/6\/e2145\/5812602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,3,27]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa152","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,3,27]]}}}